Kiniksa Pharmaceuticals International (KNSA) Stock Overview
A biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for KNSA from our risk checks.
KNSA Community Fair Values
Create NarrativeSee what 38 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Kiniksa Pharmaceuticals International, plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$55.11 |
| 52 Week High | US$59.87 |
| 52 Week Low | US$26.27 |
| Beta | 0.12 |
| 1 Month Change | 2.72% |
| 3 Month Change | 19.60% |
| 1 Year Change | 93.78% |
| 3 Year Change | 256.47% |
| 5 Year Change | 266.67% |
| Change since IPO | 183.05% |
Recent News & Updates
Analysis Article • Jun 17
Kiniksa Pharmaceuticals International (KNSA) Stock Could Be 18% Undervalued After Strong Buy Upgrade
The recent upgrade of Kiniksa Pharmaceuticals International (KNSA) to a Zacks Rank #1 Strong Buy, driven by higher earnings estimates, has put fresh attention on the stock and its current valuation backdrop. See our latest analysis for Kiniksa Pharmaceuticals International. At a share price of $52.30, Kiniksa Pharmaceuticals International has seen the 7-day share price return rise 7.39%, while the 90-day share price return of 15.84% and 1-year total shareholder return of 87.12% reflect recent...
Narrative Update • Jun 09
KNSA: Pericarditis Exposure Will Drive Future Earnings Sensitivity And Upside Potential
Analysts have nudged their fair value estimate for Kiniksa Pharmaceuticals International up from $50.00 to $57.00, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E after a series of recent price target increases from major research firms. Analyst Commentary Recent Street research has clustered around higher price targets for Kiniksa Pharmaceuticals International, with firms adjusting their models for discount rates, revenue trajectories, profit margins, and assumed future P/E multiples.
Narrative Update • May 26
KNSA: Recurrent Pericarditis Execution And Prescriber Depth Will Support Future Upside
Analysts have raised their blended price target for Kiniksa Pharmaceuticals International to $63.50 from $55.88, citing updated views on fair value, profitability, and forward P/E assumptions following recent Street research revisions from firms including Wedbush, Canaccord, Citi, and Jefferies. Analyst Commentary Recent research updates cluster around higher price targets, with analysts focusing on how current execution and revenue trends compare with prior expectations and what that implies for fair value and P/E assumptions.
Narrative Update • May 03
KNSA: Future Upside Will Stem From Recurrent Pericarditis Market Leadership
Analysts have nudged the fair value estimate for Kiniksa Pharmaceuticals International up by $4 to $72, citing recent price target increases from several firms that highlight updated assumptions for revenue growth, profitability, and the stock's future P/E multiple. Analyst Commentary Recent Street research points to a clear tilt toward optimism around Kiniksa Pharmaceuticals International, with several bullish analysts lifting price targets and initiating coverage at premium levels to the current fair value estimate.Recent updates
Analysis Article • Jun 17
Kiniksa Pharmaceuticals International (KNSA) Stock Could Be 18% Undervalued After Strong Buy Upgrade
The recent upgrade of Kiniksa Pharmaceuticals International (KNSA) to a Zacks Rank #1 Strong Buy, driven by higher earnings estimates, has put fresh attention on the stock and its current valuation backdrop. See our latest analysis for Kiniksa Pharmaceuticals International. At a share price of $52.30, Kiniksa Pharmaceuticals International has seen the 7-day share price return rise 7.39%, while the 90-day share price return of 15.84% and 1-year total shareholder return of 87.12% reflect recent...Narrative Update • Jun 09
KNSA: Pericarditis Exposure Will Drive Future Earnings Sensitivity And Upside Potential
Analysts have nudged their fair value estimate for Kiniksa Pharmaceuticals International up from $50.00 to $57.00, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E after a series of recent price target increases from major research firms. Analyst Commentary Recent Street research has clustered around higher price targets for Kiniksa Pharmaceuticals International, with firms adjusting their models for discount rates, revenue trajectories, profit margins, and assumed future P/E multiples.Narrative Update • May 26
KNSA: Recurrent Pericarditis Execution And Prescriber Depth Will Support Future Upside
Analysts have raised their blended price target for Kiniksa Pharmaceuticals International to $63.50 from $55.88, citing updated views on fair value, profitability, and forward P/E assumptions following recent Street research revisions from firms including Wedbush, Canaccord, Citi, and Jefferies. Analyst Commentary Recent research updates cluster around higher price targets, with analysts focusing on how current execution and revenue trends compare with prior expectations and what that implies for fair value and P/E assumptions.Narrative Update • May 03
KNSA: Future Upside Will Stem From Recurrent Pericarditis Market Leadership
Analysts have nudged the fair value estimate for Kiniksa Pharmaceuticals International up by $4 to $72, citing recent price target increases from several firms that highlight updated assumptions for revenue growth, profitability, and the stock's future P/E multiple. Analyst Commentary Recent Street research points to a clear tilt toward optimism around Kiniksa Pharmaceuticals International, with several bullish analysts lifting price targets and initiating coverage at premium levels to the current fair value estimate.Seeking Alpha • Apr 29
Kiniksa: Increased Outlook For Arcalyst, Augmented By Pipeline Maturation
Summary Kiniksa Pharmaceuticals continues to outperform, with Arcalyst net sales poised to surpass my previous bullish estimates. Arcalyst captured 18% of the recurrent pericarditis market by end-2025, with average therapy duration rising to three years and further upside from a new consumer awareness campaign. KPL-387, a next-generation IL-1 antibody, is set for phase 2 proof-of-concept data in H2 2026, offering improved economics and patient convenience compared to Arcalyst. Kiniksa’s upside is underpinned by strong Arcalyst execution, pipeline optionality, and limited near-term competitive threats, though longer-term competition from Eli Lilly warrants monitoring. Read the full article on Seeking AlphaNarrative Update • Apr 18
KNSA: Future Upside Will Stem From Recurrent Pericarditis Leadership
Analysts have lifted their price target on Kiniksa Pharmaceuticals International by $5, citing Arcalyst revenue tracking in line with or ahead of prior estimates and supportive views on the company's position in recurrent pericarditis and broader inflammatory cardiovascular diseases. Analyst Commentary Bullish analysts are highlighting Kiniksa Pharmaceuticals International as a focused commercial biotech story, pointing to Arcalyst and its role in recurrent pericarditis as the key driver behind recent price target increases.Narrative Update • Apr 04
KNSA: Future Upside Will Arise From Recurrent Pericarditis Market Penetration
Analyst price targets for Kiniksa Pharmaceuticals International have moved higher, with recent increases to $50 and $53, along with new Buy-rated coverage at $62, supported by Arcalyst revenue that matched or exceeded prior estimates and continued expansion in prescriber breadth, depth, and treatment duration. Analyst Commentary Bullish analysts are framing Kiniksa as a commercial stage biotech story that is already generating meaningful revenue from Arcalyst, rather than an early pipeline only name.Narrative Update • Mar 20
KNSA: Future Upside Will Be Driven By Recurrent Pericarditis Market Leadership
Analysts have raised the fair value estimate for Kiniksa Pharmaceuticals International from $62.00 to $68.00. This reflects updated views on Arcalyst revenue performance, the broader pericarditis treatment market opportunity, and a higher assumed future P/E multiple, despite slightly lower projected revenue growth and profit margin.Narrative Update • Mar 06
KNSA: Pericarditis Market Opportunity And Single-Drug Concentration Will Shape Outlook
The analyst fair value estimate for Kiniksa Pharmaceuticals International has risen from $38.00 to $50.00, as analysts point to Arcalyst revenue performance in line with or above prior expectations and expanding prescriber usage, alongside fresh Buy initiations with higher price targets in the $50 to $62 range. Analyst Commentary Recent research commentary on Kiniksa Pharmaceuticals International has centered on Arcalyst performance and the company’s position in treating recurrent pericarditis and other inflammatory cardiovascular conditions.Narrative Update • Feb 20
KNSA: Recurrent Pericarditis Opportunity And Strong Prescriber Adoption Will Drive Future Upside
Narrative Update The analyst price target for Kiniksa Pharmaceuticals International has edged up from $55 to about $55.88. Analysts point to the company's Arcalyst franchise, recent coverage initiations, and the size of the recurrent pericarditis treatment market as key supports for their updated view.Narrative Update • Feb 06
KNSA: Strong Prescriber Adoption And Guidance Outperformance Will Support Future Upside
Narrative Update on Kiniksa Pharmaceuticals International Analysts recently nudged their price target on Kiniksa Pharmaceuticals International higher to $50 from $48, pointing to stronger than guided Arcalyst revenue and continued breadth and depth of prescriber adoption with longer treatment duration as key supports for the revision. Analyst Commentary Analysts raising their target on Kiniksa are basing their view on the latest Arcalyst revenue update and how that feeds into expectations for execution and growth.Narrative Update • Jan 22
KNSA: Strong Guidance And Execution Will Support Future Earnings Upside
Narrative Update on Kiniksa Pharmaceuticals International Analysts nudged their fair value estimate for Kiniksa Pharmaceuticals International to $55.00 from $54.71, citing the recent price target increase to $50, which followed Arcalyst revenue that came in above prior estimates and guidance, supported by broader prescriber adoption and longer treatment duration. Analyst Commentary Recent Street commentary on Kiniksa Pharmaceuticals International centers on Arcalyst performance and what that might mean for execution and valuation over the medium term.Narrative Update • Jan 08
KNSA: Higher 2025 Sales Guidance Will Support Future Earnings Upside
Analysts have nudged up their price target for Kiniksa Pharmaceuticals International to about US$54.71 from roughly US$54.00. The change reflects updated assumptions around slightly higher revenue growth, a marginally different discount rate, modestly lower profit margin expectations, and a somewhat higher future P/E multiple.Narrative Update • Dec 21
KNSA: Earnings Upside Will Be Driven By Next Generation Candidate Potential
Analysts have raised their price target on Kiniksa Pharmaceuticals International from $55 to $62 as they anticipate a pivotal growth phase driven by the ongoing ramp of Arcalyst and the potential earnings upside from next generation candidate KPL-387. Analyst Commentary Bullish analysts highlight that Kiniksa is entering what they characterize as a pivotal stage in its growth trajectory, supported by the accelerating commercial performance of Arcalyst and the emerging optionality from KPL-387.Narrative Update • Dec 07
KNSA: Future Earnings Will Rise As Pivotal Launch Stage Gains Momentum
Analysts have raised their price target on Kiniksa Pharmaceuticals International from $54.00 to $60.00, citing what they view as a pivotal stage for the company, as Arcalyst's launch accelerates and KPL-387 offers the potential for more favorable dosing that could extend the franchise and bolster earnings. Analyst Commentary Bullish analysts view the recent price target increase as a reflection of Kiniksa's transition from a story driven primarily by potential to one backed by visible revenue growth from Arcalyst and a clearer pathway for pipeline contributions.Narrative Update • Nov 23
KNSA: Future Earnings Will Strengthen As New Launches Gain Momentum
Analysts have maintained their price target for Kiniksa Pharmaceuticals International at $54.00 per share. Ongoing research highlights the company's stable valuation, with promising momentum from new product launches and anticipated improvements in earnings.Narrative Update • Nov 07
KNSA: Earnings Outlook Will Improve As Pipeline Expansion Advances
Kiniksa Pharmaceuticals International's fair value price target has been raised from $50.43 to $54.00. Analysts cite Arcalyst's accelerating launch and promising pipeline potential as reasons for greater earnings expectations.Narrative Update • Oct 24
Future Revenue Potential Will Advance With Deepening Market Penetration and Pipeline Progress
Kiniksa Pharmaceuticals International’s analyst price target has increased from $48.86 to $50.43. Analysts cite strengthened commercial execution, robust product launches, and ongoing expansion opportunities as supporting factors for their upward revision.Narrative Update • Oct 10
Broader Biologic Adoption Will Unlock Undervalued Market Potential
Kiniksa Pharmaceuticals' analyst price target has increased from $47 to about $48.86. Analysts cite continued commercial momentum, expanding product opportunities, and a positive earnings outlook as drivers of the higher valuation.Narrative Update • Sep 26
Broader Biologic Adoption Will Unlock Undervalued Market Potential
Kiniksa Pharmaceuticals International’s consensus price target was modestly raised to $47.00 on the back of strong commercial execution, robust launch momentum, and continued outperformance, reflecting optimism on deeper penetration and expansion opportunities. Analyst Commentary Strong commercial execution driving revenue outperformance.
New Narrative • Apr 28
New IL-1 Receptor Antagonist Trials Will Expand Therapeutic Options
Advancing KPL-387 could drive revenue growth with expanded leadership in the recurrent pericarditis market if successful.Analysis Article • Apr 23
Lacklustre Performance Is Driving Kiniksa Pharmaceuticals International, plc's (NASDAQ:KNSA) Low P/S
Kiniksa Pharmaceuticals International, plc's ( NASDAQ:KNSA ) price-to-sales (or "P/S") ratio of 3.4x might make it look...Seeking Alpha • Feb 25
Big Pipeline Updates From Kiniksa Pharmaceuticals
Summary Kiniksa Pharmaceuticals discontinued the development of abiprubart and mavrilimumab, shifting focus to next-generation IL-1 monoclonal antibodies for recurrent pericarditis. New candidates KPL-387 and KPL-1161 should improve convenience and adherence for patients and extend the commercial life of the company's recurrent pericarditis franchise. These new candidates are also wholly owned and Kiniksa would not have to share profits with Regeneron. In the meantime, Arcalyst should continue to deliver strong growth and I see room for upward revisions to this year's $560-580 million net sales guidance range. Kiniksa is well-funded with $243 million in cash and positive cash flows, supporting the new pipeline strategy. Read the full article on Seeking AlphaSeeking Alpha • Feb 13
Kiniksa Pharmaceuticals: Strong Improvement In Arcalyst Revenue, But Risks Remain
Summary Kiniksa Pharmaceuticals International, plc's Arcalyst is gaining traction with significant revenue growth, driven by its unique position as the only approved drug for recurrent pericarditis. The company is now cash flow positive, with strong sales team performance increasing prescriber base, prescription count, and treatment duration. Abiprubart faces competition and market risks in Sjögren’s Disease, with no current data to differentiate it from competitors. KNSA stock is attractive near 52-week lows, but taking a position is advisable only after phase 2 data for abiprubart is available. Read the full article on Seeking AlphaSeeking Alpha • Oct 07
Kiniksa Pharmaceuticals: Looking In On A Developing Growth Story
Summary Today, we look in on Kiniksa Pharmaceuticals, a fast-growing biopharma concern based in London. Revenues continue to increase at an impressive rate for its flagship drug Arcalyst and the company is moving toward profitability. The company ended the first half of 2024 with $220 million in cash, no long-term debt, and is expected to be cash flow positive for the year. Read the full article on Seeking AlphaAnalysis Article • Aug 07
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Surges 25% Yet Its Low P/S Is No Reason For Excitement
Kiniksa Pharmaceuticals International, plc ( NASDAQ:KNSA ) shares have had a really impressive month, gaining 25% after...Seeking Alpha • Jul 24
Kiniksa Pharmaceuticals: Improved Outlook For Arcalyst After Q2 Beat
Summary Kiniksa Pharmaceuticals surged after the company reported strong second quarter results and increased the full year net sales guidance range for Arcalyst. The strong performance is driven by increased demand following the recent sales force expansion. The improved outlook for Arcalyst warrants an increase in the valuation range. Kiniksa remains well-positioned to create long-term shareholder value. Read the full article on Seeking AlphaAnalysis Article • Jun 19
Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Share Price Is Matching Sentiment Around Its Revenues
You may think that with a price-to-sales (or "P/S") ratio of 4.3x Kiniksa Pharmaceuticals, Ltd. ( NASDAQ:KNSA ) is...Analysis Article • Apr 25
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
Investors in Kiniksa Pharmaceuticals, Ltd. ( NASDAQ:KNSA ) had a good week, as its shares rose 5.4% to close at...Seeking Alpha • Apr 24
Kiniksa Pharmaceuticals: Arcalyst Performs While Abiprubart Plans Take Shape
Summary Kiniksa Pharmaceuticals reported strong Q1 2024 results, with net sales of Arcalyst growing 85% YoY and 11% sequentially. Arcalyst's strong performance has driven a $10 million increase in the full-year net sales guidance range. Kiniksa plans to develop abiprubart for the treatment of Sjogren's syndrome, with a large phase 2b trial expected to start in the second half of the year. With long development timelines for abiprubart, Kiniksa faces a very dry period for its clinical pipeline and the upside in the next 2-3 years depends on Arcalyst. With a strong balance sheet and management expecting positive cash flow this year, we could see Kiniksa in-license additional clinical candidates in the following quarters. Read the full article on Seeking AlphaShareholder Returns
| KNSA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 6.2% | 1.3% | 1.4% |
| 1Y | 93.8% | 31.4% | 25.7% |
Return vs Industry: KNSA exceeded the US Biotechs industry which returned 31.4% over the past year.
Return vs Market: KNSA exceeded the US Market which returned 25.7% over the past year.
Price Volatility
| KNSA volatility | |
|---|---|
| KNSA Average Weekly Movement | 8.4% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: KNSA has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: KNSA's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 366 | Sanj Patel | www.kiniksa.com |
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage.
Kiniksa Pharmaceuticals International, plc Fundamentals Summary
| KNSA fundamental statistics | |
|---|---|
| Market cap | US$4.24b |
| Earnings (TTM) | US$73.06m |
| Revenue (TTM) | US$754.05m |
58.0x
P/E Ratio5.6x
P/S RatioIs KNSA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KNSA income statement (TTM) | |
|---|---|
| Revenue | US$754.05m |
| Cost of Revenue | US$341.93m |
| Gross Profit | US$412.11m |
| Other Expenses | US$339.05m |
| Earnings | US$73.06m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.95 |
| Gross Margin | 54.65% |
| Net Profit Margin | 9.69% |
| Debt/Equity Ratio | 0% |
How did KNSA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/20 20:43 |
| End of Day Share Price | 2026/06/18 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Kiniksa Pharmaceuticals International, plc is covered by 12 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Geoffrey Meacham | BofA Global Research |
| Edward Nash | Canaccord Genuity |
| Geoffrey Meacham | Citigroup Inc |